Tiziana Life Sciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

19.08.24	Tiziana Life Appoints Ivor Elrifi As CEO (RTTNews)
18.10.23	Tiziana : FDA Allows Multiple Sclerosis Patients To Take Home & Self-administer Intranasal Foralumab (RTTNews)
16.10.23	Tiziana Life Sciences Reports Positive 6-month Data With Intranasal Foralumab In Multiple Sclerosis (RTTNews)
15.07.22	Tiziana Life Sciences CEO Kunwar Shailubhai Resigns (RTTNews)
21.10.21	Share Capital Consolidation and Commencement of trading in the New Tiziana Shares on NASDAQ (GlobeNewswire)
20.10.21	Tiziana Life Sciences - Scheme Effective Date (GlobeNewswire)
20.10.21	Tiziana Life Sciences plc: PDMR Dealing (GlobeNewswire)
19.10.21	Tiziana Life Sciences plc: Court Sanctions the Scheme of Arrangement and approves Reduction of Capital (GlobeNewswire)
28.09.21	Tiziana Life Sciences plc: PDMR Dealing (GlobeNewswire)
27.09.21	Tiziana Life Sciences Plc - Results of Court Meeting and General Meeting (GlobeNewswire)
24.09.21	Tiziana Life Sciences plc - Interim Results for the Six Months Ended 30 June 2021 (GlobeNewswire)
07.09.21	Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cance (GlobeNewswire)
03.09.21	Tiziana Life Sciences plc Posting of Scheme Document and Notice of Meetings (GlobeNewswire)
02.09.21	Pre-market Movers: FCUV, TLSA, ZSAN, METX, ASMB… (RTTNews)
02.09.21	Precision BioSciences, Tiziana Life Sciences Sign Exclusive License Deal For Foralumab (RTTNews)
02.09.21	Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Cand (GlobeNewswire)
20.08.21	Tiziana Life Sciences plc files scheme of arrangement to effect a corporate reorganisation and, if approved, the delisting of its ordinary shares in London and the direct listing of common shares in t (GlobeNewswire)
18.08.21	Pre-market Movers: VRPX, GLG, PTIX, GLBS, AMYT, ALC… (RTTNews)
17.08.21	Pre-market Movers: CRDL, LMFA, FBRX, QLGN, SMFR… (RTTNews)
17.08.21	Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to (GlobeNewswire)
02.07.21	Tiziana Life Sciences plc - Distribution Dates for shares and ADRs in Accustem Sciences Limited (GlobeNewswire)
30.06.21	Dr Howard Weiner, Chairman of the Tiziana Scientific Advisory Board, to give an interview on Bloomberg Markets at 1.50pm ET today (GlobeNewswire)
25.06.21	Tiziana Life Sciences plc (the "Company") Result of Annual General Meeting (GlobeNewswire)
23.06.21	Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Mono (GlobeNewswire)
21.06.21	Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs (GlobeNewswire)
17.06.21	Tiziana Responds to UK Call for Development of Innovative ‘Take Home’ Treatments for COVID-19 Disease (GlobeNewswire)
02.06.21	Tiziana Life Sciences plc ("Tiziana" or the “Company”) Posting of Notice of Annual General Meeting (GlobeNewswire)
26.05.21	Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers (GlobeNewswire)
25.05.21	Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Anti (GlobeNewswire)
07.05.21	Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report (GlobeNewswire)
05.05.21	Tiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Ad (GlobeNewswire)
27.04.21	Tiziana Life Sciences to participate in a Fireside Chat on 28 April 2021 at 10:30 a.m. EDT (GlobeNewswire)
13.04.21	Tiziana Life Sciences plc Announces Plans to List Accustem Sciences Limited in the U.S. (GlobeNewswire)
30.03.21	Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Und (GlobeNewswire)
30.03.21	Tiziana Life Sciences plc: Accustem Update (GlobeNewswire)
30.03.21	Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody (GlobeNewswire)
29.03.21	Updated - Gabriele Cerrone, Chairman of Tiziana Life Sciences to give interview on Bloomberg Television US at 1:50 PM ET Tomorrow, 30 March 2021 (GlobeNewswire)
29.03.21	Tiziana Life Sciences plc ("Tiziana" or the "Company") - Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give interview on Bloomberg Television US at 1:20 PM ET Today (GlobeNewswire)
26.02.21	Tiziana Life Sciences Interview to Air on Bloomberg Television US on The RedChip Money Report (GlobeNewswire)
16.02.21	Tiziana Life Sciences to Present at the BIO CEO & Investor Digital Conference (GlobeNewswire)
05.02.21	Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director (GlobeNewswire)
03.02.21	Tiziana Life Sciences CEO Discusses COVID-19 Trial Data in Exclusive Interview (GlobeNewswire)
02.02.21	Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil (GlobeNewswire)
27.01.21	Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana Files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission (GlobeNewswire)
20.01.21	Tiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual Oncology Investor Conference on 21 January 2021 at 3 pm ET/8 pm GMT (GlobeNewswire)
20.01.21	Tiziana Life Sciences plc ("Tiziana" or the "Company") - AIM Delisting and Admission to the Standard Listing Segment of Main Market (GlobeNewswire)
13.01.21	Stock Alert: Tiziana Life Sciences Gains 25% (RTTNews)
13.01.21	Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer (GlobeNewswire)
11.01.21	Tiziana Life Sciences to participate at J.P. Morgan Healthcare Conference 2021 (GlobeNewswire)
11.01.21	Tiziana Life Sciences to Present at Biotech Showcase Digital 2021 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Tiziana Life Sciences PLC (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten